Update on in-vivo preclinical research models in adrenocortical carcinoma
- Resource Type
- Authors
- Katja Kiseljak-Vassiliades; Margaret E. Wierman; Adwitiya Kar
- Source
- Curr Opin Endocrinol Diabetes Obes
- Subject
- Endocrinology, Diabetes and Metabolism
Mice, Nude
030209 endocrinology & metabolism
030204 cardiovascular system & hematology
medicine.disease_cause
Article
Mice
03 medical and health sciences
Preclinical research
0302 clinical medicine
Endocrinology
In vivo
Adrenocortical Carcinoma
Tumor Microenvironment
Internal Medicine
Animals
Humans
Medicine
Adrenocortical carcinoma
Tumor microenvironment
Nutrition and Dietetics
business.industry
Extramural
medicine.disease
Xenograft Model Antitumor Assays
Adrenal Cortex Neoplasms
Disease Models, Animal
Cell Transformation, Neoplastic
Genetically Engineered Mouse
Cancer research
Drug Screening Assays, Antitumor
business
Carcinogenesis
- Language
- ISSN
- 1752-2978
1752-296X
Purpose of review The aim of this review is to summarize recent advances on development of in vivo preclinical models of adrenocortical carcinoma (ACC). Recent findings Significant progress has been achieved in the underlying molecular mechanisms of adrenocortical tumorigenesis over the last decade, and recent comprehensive profiling analysis of ACC tumors identified several genetic and molecular drivers of this disease. Therapeutic breakthroughs, however, have been limited because of the lack of preclinical models recapitulating the molecular features and heterogeneity of the tumors. Recent publications on genetically engineered mouse models and development of patient-derived ACC xenografts in both nude mice and humanized mice now provide researchers with novel tools to explore therapeutic targets in the context of heterogeneity and tumor microenvironment in human ACC. Summary We review current in-vivo models of ACC and discuss potential therapeutic opportunities that have emerged from these studies.